Diabetes Dialogue: Prescribing Tirzepatide, Biosimilar Insulins, & Misdiagnosis of T1D

from Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives · host Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

In this edition of Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives our hosts discuss the experiences of their prescribing tirzepatide (Mounjaro) to patients and what types of issues patients have encountered, the prospect of new biosimilar insulins that may be coming to the market, and the misdiagnosis of type 1 diabetes in adult patients.

Episode metadata supplied by the publisher feed · Published Jun 24, 2022

Embed this episode

Attribution link and audio player

What this episode covers

In this episode, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss their experiences with prescribing tirzepatide (Mounjaro) and what issues patients have encountered, the prospect of new biosimilar insulins coming to the market, and the misdiagnosis of type 1 diabetes in adult patients.

Distinct summary based on available episode metadata or transcript content.

Ready to play

Diabetes Dialogue: Prescribing Tirzepatide, Biosimilar Insulins, & Misdiagnosis of T1D

0:00 24:17

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives?

This episode is 24 minutes long.

When was this Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives episode published?

This episode was published on June 24, 2022.

Can I download this Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!